Qingdao Biopeptek Co., Ltd.: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Qingdao Biopeptek Co., Ltd.?

Yes. FDA’s import refusal records list 4 refused shipment lines declared as made by Qingdao Biopeptek Co., Ltd. (China) whose FDA product code names semaglutide and tirzepatide, from Dec 4, 2023 to Jan 25, 2024. 3 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Qingdao
FEI numbers on the lines
3009110908
Refused lines
4
Lines with an Import Alert 66-80 API or powder code
3
Drugs named in the product codes
Semaglutide, Tirzepatide
Refusal dates
Dec 4, 2023 to Jan 25, 2024

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Qingdao Biopeptek Co., Ltd. is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Jan 25, 2024China61PCR72 SEMAGLUTIDE (ANTI-DIABETIC)NonSterile PowderLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
AEK-3647198-3/11/1
Dec 6, 2023China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.

FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.
AEK-3571990-3/11/1
Dec 6, 2023China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.
AEK-3572197-4/11/1
Dec 4, 2023China61PAY72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.AEK-3647249-4/11/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.3
FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.3
LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.2

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

4 lines from FDA files read Nov 15, 2026.